Apr 10, 2017
Posted: Apr 10, 2017
Last night our Chief Executive Officer Professor Martin Gibson was accompanied by our Chief Operating Officer Marie Kane to the Annual Clinical and Research Excellence Awards held in Boston, USA.
In February NorthWest EHealth (NWEH) found out that we had been shortlisted as a finalist in the ‘Best Patient-Focused Technological Development category’ for our Linked Database System Tool (LDS). LDS has been developed to support the collection of real world evidence, from individually consented patients, for research.
Combining data feeds from hospital and primary care systems with supplementary feeds from pharmacy, community and external NHS organisations, the LDS is linked to a fully validated electronic Case Report Form (eCRF). This ensures prompt safety monitoring and reporting of adverse events using the ICH E2B standard. The system collects ongoing information about each study participant’s medications, symptoms and use of healthcare facilities, and is used both to provide safety monitoring and to collect research data for the study.
In the ‘Best Patient-Focused Technological Development’ category NWEH were up against some international names from the world of pharma including organisations such as PAREXEL Int. AMRA and CRF Health. To be recognised as a finalist in such a prestigious category for our LDS tool and the hard work all of the staff at NWEH put in to improve patients’ lives is an honour. Just being a finalist and the recognition of our team’s achievements with LDS has been a fantastic experience for NWEH.
So to be announcing that we have won the ‘Best Patient-Focused Technological Development’ award at the Annual Clinical and Research Excellence Awards is overwhelming and has been a wonderful surprise. We have always known that LDS is worthy of acclaim as it has enabled us to be the only organisation in the world who has been able to have evaluated safety and effectiveness of a pre-license medicine in a real-world setting, allowing us to get medicines to patients quicker and cheaper.
We are excited about the future and how the next level of our technology can help us to continue to improve patients’ lives.